DFDavide Fumagalli

Davide Fumagalli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Davide Fumagalli has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Environmental risk and market approval for human pharmaceuticals

    by Davide Fumagalli

    This paper contributes to the growing discussion about how to mitigate pharmaceutical pollution, which is a threat to human, animal, and environmental health as well as a potential driver of antimicrobial resistance. It identifies market approval of pharmaceuticals as one of the most powerful ways to shape producer behavior and highlights that applying this tool raises ethical issues given that it might impact patients’ access to medicines. The paper identifies seven different policy options that progressively give environmental considerations increased priority in the approval process, identifies ethically relevant interests affected by such policies, and makes explicit tensions and necessary tradeoffs between these interests. While arguing that the current European regulation gives insufficient weight to environmental considerations, the paper highlights concerns with the strongest policy options, on the grounds that these may very well endanger patients’ access to effective medication.


  • Open Access

    Antimicrobial Resistance, One Health Interventions and the Least Restrictive Alternative Principle

    by Davide Fumagalli

    Antimicrobial resistance (AMR) is increasingly recognised as a threat to human, animal and environmental health. In an effort to counter this threat, several intervention plans have been proposed and implemented by states and organisations such as the WHO. A One Health policy approach, which targets multiple domains (healthcare, animal husbandry and the environment), has been identified as useful for curbing AMR. Johnson and Matlock have recently argued that One Health policies in the AMR context require special ethical justification because of the so-called least restrictive alternative principle. This article analyses and rejects two assumptions that this argument relies on. The first assumption is that One Health policies are generally more restrictive than their alternatives because they target more domains and impact more people. The second assumption is that the least restrictive alternative principle has a special normative importance in that it establishes a systematic presumption in favour of the least restrictive policy options. Once these assumptions are rejected, the use of One Health policies on AMR can be justified more easily than Johnson and Matlock argue.


  • Open Access

    Pharmaceutical Pollution from Human Use and the Polluter Pays Principle

    by Erik Malmqvist, Davide Fumagalli, Christian Munthe, D G Joakim Larsson

    Human consumption of pharmaceuticals often leads to environmental release of residues via urine and faeces, creating environmental and public health risks. Policy responses must consider the normative question how responsibilities for managing such risks, and costs and burdens associated with that management, should be distributed between actors. Recently, the Polluter Pays Principle (PPP) has been advanced as rationale for such distribution. While recognizing some advantages of PPP, we highlight important ethical and practical limitations with applying it in this context: PPP gives ambiguous and arbitrary guidance due to difficulties in identifying the salient polluter. Moreover, when PPP does identify responsible actors, these may be unable to avoid or mitigate their contribution to the pollution, only able to avoid/mitigate it at excessive cost to themselves or others, or excusably ignorant of contributing. These limitations motivate a hybrid framework where PPP, which emphasizes holding those causing large-scale problems accountable, is balanced by the Ability to Pay Principle (APP), which emphasizes efficiently managing such problems. In this framework, improving wastewater treatment and distributing associated financial costs across water consumers or taxpayers stand out as promising responses to pharmaceutical pollution from human use. However, sound policy depends on empirical considerations requiring further study.


  • Open Access

    Antibiotic Resistance, Meat Consumption and the Harm Principle

    by Davide Fumagalli

    This paper vindicates using the harm principle (HP) to justify restricting consumer’s access to meat products in light of the impact that it has on the development of antibiotic resistance (ABR). In particular, the study claims that, since an individual instance of consumption, or purchase of meat, meaningfully contributes to the development of ABR in farming environments, a state intervention limiting consumer freedom would be legitimate. The causal impact of individuals in greater-scale problems has long been debated and dismissed as not relevant. The study analyzed two possible formulations of the inconsequentialist objection. While the first formulation, which maintains that individuals have no impact, can be rejected independently of the context of application, rejecting the second formulation, which maintains that this impact is insufficient to warrant applying HP, is more difficult. In order to successfully respond to this version of inconsequentialism, the paper vindicates the value of considering ABR and ABR-related harm within a more traditional expected utility arguments.